OrsoBio
Eisuke Murakami currently serves as Senior Director of Research at OrsoBio, a position held since November 2022, and previously held a similar role at The Liver Company (TLC) since July 2021. Prior experience includes a tenure at Gilead Sciences from January 2012 to July 2021, where Eisuke progressed through roles including Principal Scientist, Senior Scientist I, and Research Scientist II, focusing on DMPK. Eisuke began the professional career at Pharmasset, Inc. as Sr. Scientist in Biology from July 2004 to January 2012, specializing in Biochemistry, Molecular Pharmacology, and In Vitro Drug Metabolism, after serving as an Associate Research Scientist at Yale University School of Medicine from June 2000 to June 2004, concentrating on Biochemistry and Pharmacology. Eisuke earned a Ph.D. in Biochemistry from the University of Nebraska-Lincoln between 1995 and 2000.
This person is not in any teams
OrsoBio
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.